TABLE 1

Baseline clinical features of patients with type 2 diabetes

Ala carriers
Pro/Pro homozygotes
OverallACEi yesACEi noOverallACEi yesACEi no
n1779186942464478
Age (years)62.6 ± 8.361.8 ± 8.063.4 ± 8.662.3 ± 8.062.1 ± 8.062.4 ± 8.1
Male subjects86 (48.6)46 (50.6)40 (46.5)503 (53.4)253 (54.5)250 (52.3)
BMI (kg/m2)29.4 ± 4.529.4 ± 4.829.3 ± 4.229.0 ± 4.729.1 ± 5.029.0 ± 4.5
Diabetes duration (years)7.7 ± 7.27.7 ± 7.17.8 ± 7.57.8 ± 6.57.6 ± 6.68.1 ± 6.5
Smokers67 (37.9)40 (44.0)27 (31.4)399 (42.4)214 (46.1)185 (38.7)
    Current13 (7.3)9 (9.9)4 (4.7)121 (12.9)64 (13.8)57 (11.9)
    Never110 (62.2)51 (56.0)59 (68.6)543 (57.6)250 (53.9)293 (61.3)
    Former54 (30.5)31 (34.1)23 (26.7)278 (29.5)150 (32.3)128 (26.8)
A1C (%)5.9 ± 1.56.0 ± 1.65.9 ± 1.45.8 ± 1.35.7 ± 1.45.8 ± 1.3
SBP (mmHg)151.2 ± 13.3151.4 ± 12.9151.1 ± 13.8150.6 ± 14.5150.3 ± 14.3150.9 ± 14.6
DBP (mmHg)87.5 ± 7.688.0 ± 7.787.1 ± 7.587.4 ± 7.687.2 ± 7.987.6 ± 7.3
Serum creatinine (mg/dl)0.91 ± 0.160.91 ± 0.170.90 ± 0.160.91 ± 0.160.90 ± 0.150.91 ± 0.17
Triglycerides (mg/dl)130.8 (120.8–141.7)127.2 (113.4–142.7)134.7 (120.4–150.7)127.4 (123.4–131.5)128.6 (123.1–134.4)126.2 (120.6–132.1)
Total cholesterol (mg/dl)211.3 ± 37.5206.3 ± 36.1216.4 ± 38.6209.3 ± 36.3206.5 ± 35.1211.9 ± 37.3
HDL cholesterol (mg/dl)47.0 ± 12.347.4 ± 11.746.5 ± 13.046.9 ± 12.046.9 ± 12.447.0 ± 11.6
AER (μg/min)5.2 (4.8–5.7)5.1 (4.5–5.8)5.4 (4.7–6.2)5.7 (5.5–5.9)5.6 (5.2–5.9)5.8 (5.5–6.2)
  • Data are means ±SD, n (%), or geometric means (95% CIs). Differences between Ala carriers and Pro/Pro homozygotes (overall) as well as between ACEi yes and ACEi no (within each genotype group) were not significant. ACEi, ACE inhibitor therapy; DBP, diastolic blood pressure; and SBP, systolic blood pressure.